Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination

Transplantation

Volumn 74, Issue 11, 2002, Pages 1560-1567

  Gonwa, Thomas A ^a,f   Hricik, Donald E ^b   Brinker, Karl ^c   Grinyo, Josep M ^d   Schena, Francesco P ^e  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Dallas Nephrology Associates   (United States)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e UNIVERSITY OF BARI   (Italy)

^f Mayo Clinic Transplant Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; RAPAMYCIN;

ADULT; ARTICLE; CADAVER; CALCULATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ELIMINATION; DRUG SAFETY; DYSPNEA; EDEMA; EUROPE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; UNITED STATES;

EID: 0037115133     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200212150-00013     Document Type: Article

References (26)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
2. Cecka JM. The UNOS Scientific Renal Transplant Registry: Ten years of kidney transplants. Clin Transpl 1997; 1-14.
3. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340.
4. Sehgal SN. Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995; 17: 660-665.
5. Liu J, Farmer JD Jr, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66: 807-815.
6. Kahan BD, Chang JY, Sehgal SN. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991; 52: 185-191.
7. Stepkowski SM, Kahan BD. Rapamycin and cyclosporine synergistically prolong heart and kidney allograft survival. Transplant Proc 1991; 23: 3262-3264.
8. Ikonen TS, Gummert JF, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates. Transplantation 2000; 70: 969-975.
9. Kahan BD, for the Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study. Lancet 2000; 356: 194-202.
10. MacDonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280.
11. DiJoseph JF, Sharma RN, Chang JY. The effect of rapamycin on kidney function in the Sprague-Dawley rat. Transplantation 1992; 53: 507-513.
12. Golbaekdal K, Nielsen CB, Djushuus JC, et al. Effects of rapamycin on renal hemodynamics, water and sodium excretion, and plasma levels of angiotensin II, aldosterone, atrial natriuretic peptide, and vasopressin in pigs. Transplantation 1994; 58: 1153-1157.
13. Groth CG, Backman L, Morales JM, et al., for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 1036-1042.
14. Kreis H, Cisterne JM, Land W, et al., for the Sirolimus European Renal Transplant Study Group. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252-1260.
15. Jones K, Saadat-Lajevard S, Lee T, et al. An immunoassay for the measurement of sirolimus. Clin Ther 2000; 22(suppl B): B49-B61.
16. Maleki S, Graves S, Becker S, et al. Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin Ther 2000; 22(suppl B): B25-B37.
17. Holt DW, Lee T, Jones K, et al. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin Chem 2000; 46: 1179-1183.
18. Olyaei AJ, de Mattos AM, Bennett WM. Immunosuppressant-induced nephropathy: Pathophysiology, incidence and management. Drug Safety 1999; 21: 471-488.
19. Benigni A, Bruzzi I, Mister M, et al. Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999; 55: 674-685.
20. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a U. S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736-1740.
21. Weir MR. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation. Transpl Proc 2001; 33(suppl 4A): 19S-28S.
22. Johnson CP, McBride M, Cherikh WS, et al. Renal function in the first year after transplantation predicts long-term survival. Am J Transpl 2001; 1(suppl 1): 146.
23. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
24. McGrath JS, Shehata M. Chronic allograft nephropathy: Prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution. Transpl Proc 2001; 33: 2193-2195.
25. Johnson RW, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
26. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 11(suppl 15): S1-S86, 2000.